α1Proteinase Inhibitor Regulates CD4+ Lymphocyte Levels and Is Rate Limiting in HIV-1 Disease
Figure 1
Correlation between α1PI, IgG-α1PI immune complexes, and CD4+ lymphocytes in HIV-1 infected subjects.
(A) In subjects with >220 CD4 cells/µl, CD4+ lymphocyte levels correlate with active α1PI (r2 = 0.927, p<0.0001, n = 26). CD4+ lymphocyte levels also correlate with inactive α1PI, (r2 = 0.906, p<0.0001, n = 26). Subjects receiving protease inhibitor therapy are depicted by red squares. All other subjects are depicted by black circles. In the 9 subjects with <220 CD4 cells/µl, no correlation was found to exist between CD4+ lymphocyte levels and active α1PI. Non-linear regression was performed using a 3 parameter Sigmoid curve with power of test α = 0.05. In this population, all variables were found to have normality and constant variation. (B) In 8 of 35 subjects, IgG-α1PI immune complexes were detected and were correlated with CD4+ lymphocyte levels (r2 = 0.822, p = 0.05) and with inactive α1PI (r2 = 0.988, p<0.0001).